Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. reports on events occurring on December 22, 2015, specifically the results of the Company's Annual Meeting of Stockholders. The filing also details prior compensation committee actions from September and November 2015 regarding equity plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance, voting results, and equity plan amendments.
Material Changes and Voting Results
At the Annual Meeting, stockholders approved three key matters:
- Election of Director: Charles S. Ryan was elected as a Class I director with 1,365,608 votes for, 758 withheld, and 390,889 broker non-votes.
- Equity Plan Amendment: Stockholders approved increasing the number of shares authorized under the 2010 Equity Participation Plan from 1,000,000 to 2,250,000. The vote was 1,360,461 for, 5,904 against, and 1 abstention.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2015. The vote was 1,756,805 for, 7 against, and 443 abstentions.
Management Commentary, Risks, and Unusual Items
Equity Grants and Vesting:
- On September 4, 2015, the Compensation Committee granted ten-year options for an aggregate of 505,250 shares at an exercise price of $7.00 per share to executive officers and directors, including CEO Mark Weinreb (208,000 shares).
- These options were contingent upon stockholder approval of the increase in authorized shares from 1,000,000 to 2,250,000.
- Following the successful vote on December 22, 2015, these options are now exercisable in accordance with approved vesting schedules.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard governance activities reported.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 1,250,000 share increase in the equity plan.
- Confirm the specific vesting schedules for the 505,250 options granted to executives at $7.00 per share.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Monitor future filings for the actual issuance of shares under the amended 2010 Equity Participation Plan.